VKTX Sarah Kathryn Rouan buys $60K worth of shares
Apr 03, 2025, 4:33 AM
0.00%
What does VKTX do
Viking Therapeutics, based in San Diego, develops therapies for metabolic and endocrine disorders, including VK2809 for NASH, VK0214 for X-ALD, and VK2735 for metabolic issues. The company went public on April 29, 2015, and has 28 employees.
Sarah Kathryn Rouan bought 2,480 shares of VKTX on 31 March at $24.15 per share, worth a total of $60K. They now own 1,240 VKTX shares, or a 200% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
